Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01571232 · ClinicalTrials.gov registry record · Phase 2
Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema
A Phase 2 study, sponsored by Retina Macula Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT01571232: Completed Phase 2 study, sponsored by Retina Macula Institute.
NCT01571232 is a Phase 2 study that has completed, run by Retina Macula Institute. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01571232, a Phase 2 study, has completed, sponsored by Retina Macula Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to test the efficacy of an 0.7 mg intravitreal dexamethasone implant (Ozurdex®) on macular leakage and visual acuity for patients with recalcitrant diabetic macular edema.
Interventions
- DRUG dexamethasone intravitreal implant
- DRUG intravitreal bevacizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2012-04 |
| Est. Completion | 2015-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01571232
The ClinicalTrials.gov registry entry for NCT01571232 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Retina Macula Institute, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which dexamethasone intravitreal implant is the first listed.
NCT01571232 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01571232 about?
NCT01571232 is a clinical study titled "Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema". The purpose of this study is to test the efficacy of an 0.7 mg intravitreal dexamethasone implant (Ozurdex®) on macular leakage and visual acuity for patients with recalcitrant diabetic macular edema.
What is the current status of trial NCT01571232?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2012-04. Estimated completion is 2015-03.
What interventions are being tested in trial NCT01571232?
The interventions under investigation include: dexamethasone intravitreal implant (DRUG), intravitreal bevacizumab (DRUG).
Who is sponsoring clinical trial NCT01571232?
This trial is sponsored by Retina Macula Institute, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.